A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 02 Aug 2024
At a glance
- Drugs SPYK 04 (Primary)
- Indications Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 31 Jul 2024 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.
- 31 Jul 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Sep 2025.
- 31 Jul 2024 Status changed from recruiting to active, no longer recruiting.